Shionogi Acquires Tetra Therapeutics, Rights to Fragile X Treatment
Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
Investigational therapy BPN14770 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of fragile X syndrome.| Fragile X News Today
Tetra Therapeutics’ investigational oral therapy BPN14770 safely and effectively improved cognitive function in men with fragile X syndrome.| Fragile X News Today
Read about the characteristic symptoms of fragile X syndrome, which range from developmental and behavioral problems to physical features.| Fragile X News Today
Fragile X syndrome is caused by low to no levels of the FMRP protein, important for brain development, due to mutations in the FMR1 gene.| Fragile X News Today
Category archive page for News.| Fragile X News Today
Blood levels of two proteins, known as MMP9 and APP, could serve as biomarkers for fragile X syndrome where genetic testing is not possible.| Fragile X News Today
Learn about fragile X syndrome, the most common cause of inherited intellectual disability and autism spectrum disorders.| Fragile X News Today
